Form 8-K - Current report:
SEC Accession No. 0001213900-24-069941
Filing Date
2024-08-16
Accepted
2024-08-16 06:03:22
Documents
14
Period of Report
2024-08-16
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ea021156901-8k_cadrenal.htm   iXBRL 8-K 31976
2 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATIO ea021156901ex3-1_cadrenal.htm EX-3.1 8585
  Complete submission text file 0001213900-24-069941.txt   222126

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cvkd-20240816.xsd EX-101.SCH 3015
4 XBRL LABEL FILE cvkd-20240816_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cvkd-20240816_pre.xml EX-101.PRE 22359
16 EXTRACTED XBRL INSTANCE DOCUMENT ea021156901-8k_cadrenal_htm.xml XML 3918
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 241214046
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)